|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
Oncology: EMEA Approval Lags
Author(s)Kevin Gopal
London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.
Advertisement
Articles in this issue
almost 25 years ago
National Crisis Supercedes Coverage Debatealmost 25 years ago
PBMs: Merck-Medco in the Hot Seatalmost 25 years ago
National Crisis Supercedes Coverage Debatealmost 25 years ago
A Five-Year Forecast: Clear Seas Ahead?almost 25 years ago
Weak Bones, Strong Marketalmost 25 years ago
Approvals: Novartis’ Silver Liningalmost 25 years ago
Pfizer and others Pitch Inalmost 25 years ago
Illegal Sales in Indiaalmost 25 years ago
Health Plan Premiums: Pharma Takes the Blamealmost 25 years ago
Little Elan Becomes a Big DealAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
3
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5